Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy

Y. Zhang, R. Stein, W. Wang, M. S. Steiner, Yi Lu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Prostate cancer is the most frequent cancer and the second leading cause of cancer deaths in men today. Novel strategies such as gene therapy are desperately needed. Viral-based vectors that are available today for gene therapy are tissue-non-specific because of constitutively active viral promoters. Consequently, the expression of the delivered therapeutic gene may occur in unintended, nontargeted tissues which may potentially cause systemic toxic effects, especially if a suicide gene is the expressed gene. To minimize potential systemic toxicity of adenoviral vectors containing toxic therapeutic genes for gene therapy, prostate-specific promoters may allow the exclusive expression of the therapeutic gene in prostate. Three different prostate-specific promoters, prostate specific antigen (PSA), probasin (PB), and mouse mammary tumor virus long terminal repeat (MMTV), were used to construct adenoviral vectors containing the β-galactosidase (β-gal) reporter gene. The expression and specificity of β-gal gene were evaluated in prostate and nonprostate cells in vitro and in vivo. In vitro, all the three prostate-specific adenoviruses transduced and expressed β-gal in prostate-derived cells, but had weak or no detectable expression of β-gal in non-prostate cells. In vivo, prostate-specific adenoviruses expressed β-gal only in prostate xenograft tumors grown in nude mice, but not in tumors derived from human bladder cancer cells. These results indicate that development of prostate-specific adenoviruses containing prostate specific promoters may be useful to better target prostate cancer for gene therapy.

Original languageEnglish (US)
Pages (from-to)158-169
Number of pages12
JournalTumor Targeting
Volume4
Issue number3
StatePublished - Nov 18 1999

Fingerprint

Neoplasm Genes
Genetic Therapy
Prostate
Prostatic Neoplasms
Adenoviridae
Genes
Poisons
Galactosidases
Mouse mammary tumor virus
Neoplasms
Second Primary Neoplasms
Terminal Repeat Sequences
Prostate-Specific Antigen
Reporter Genes
Heterografts
Urinary Bladder Neoplasms
Nude Mice
Suicide
Cause of Death
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cancer Research

Cite this

Zhang, Y., Stein, R., Wang, W., Steiner, M. S., & Lu, Y. (1999). Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy. Tumor Targeting, 4(3), 158-169.

Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy. / Zhang, Y.; Stein, R.; Wang, W.; Steiner, M. S.; Lu, Yi.

In: Tumor Targeting, Vol. 4, No. 3, 18.11.1999, p. 158-169.

Research output: Contribution to journalArticle

Zhang, Y, Stein, R, Wang, W, Steiner, MS & Lu, Y 1999, 'Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy', Tumor Targeting, vol. 4, no. 3, pp. 158-169.
Zhang, Y. ; Stein, R. ; Wang, W. ; Steiner, M. S. ; Lu, Yi. / Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy. In: Tumor Targeting. 1999 ; Vol. 4, No. 3. pp. 158-169.
@article{cc759715a5ab4ea0a97032878a61ac04,
title = "Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy",
abstract = "Prostate cancer is the most frequent cancer and the second leading cause of cancer deaths in men today. Novel strategies such as gene therapy are desperately needed. Viral-based vectors that are available today for gene therapy are tissue-non-specific because of constitutively active viral promoters. Consequently, the expression of the delivered therapeutic gene may occur in unintended, nontargeted tissues which may potentially cause systemic toxic effects, especially if a suicide gene is the expressed gene. To minimize potential systemic toxicity of adenoviral vectors containing toxic therapeutic genes for gene therapy, prostate-specific promoters may allow the exclusive expression of the therapeutic gene in prostate. Three different prostate-specific promoters, prostate specific antigen (PSA), probasin (PB), and mouse mammary tumor virus long terminal repeat (MMTV), were used to construct adenoviral vectors containing the β-galactosidase (β-gal) reporter gene. The expression and specificity of β-gal gene were evaluated in prostate and nonprostate cells in vitro and in vivo. In vitro, all the three prostate-specific adenoviruses transduced and expressed β-gal in prostate-derived cells, but had weak or no detectable expression of β-gal in non-prostate cells. In vivo, prostate-specific adenoviruses expressed β-gal only in prostate xenograft tumors grown in nude mice, but not in tumors derived from human bladder cancer cells. These results indicate that development of prostate-specific adenoviruses containing prostate specific promoters may be useful to better target prostate cancer for gene therapy.",
author = "Y. Zhang and R. Stein and W. Wang and Steiner, {M. S.} and Yi Lu",
year = "1999",
month = "11",
day = "18",
language = "English (US)",
volume = "4",
pages = "158--169",
journal = "Tumor Targeting",
issn = "1351-8488",
publisher = "Stockton Press",
number = "3",

}

TY - JOUR

T1 - Comparison of prostate specific adenoviral vectors for prostate cancer gene therapy

AU - Zhang, Y.

AU - Stein, R.

AU - Wang, W.

AU - Steiner, M. S.

AU - Lu, Yi

PY - 1999/11/18

Y1 - 1999/11/18

N2 - Prostate cancer is the most frequent cancer and the second leading cause of cancer deaths in men today. Novel strategies such as gene therapy are desperately needed. Viral-based vectors that are available today for gene therapy are tissue-non-specific because of constitutively active viral promoters. Consequently, the expression of the delivered therapeutic gene may occur in unintended, nontargeted tissues which may potentially cause systemic toxic effects, especially if a suicide gene is the expressed gene. To minimize potential systemic toxicity of adenoviral vectors containing toxic therapeutic genes for gene therapy, prostate-specific promoters may allow the exclusive expression of the therapeutic gene in prostate. Three different prostate-specific promoters, prostate specific antigen (PSA), probasin (PB), and mouse mammary tumor virus long terminal repeat (MMTV), were used to construct adenoviral vectors containing the β-galactosidase (β-gal) reporter gene. The expression and specificity of β-gal gene were evaluated in prostate and nonprostate cells in vitro and in vivo. In vitro, all the three prostate-specific adenoviruses transduced and expressed β-gal in prostate-derived cells, but had weak or no detectable expression of β-gal in non-prostate cells. In vivo, prostate-specific adenoviruses expressed β-gal only in prostate xenograft tumors grown in nude mice, but not in tumors derived from human bladder cancer cells. These results indicate that development of prostate-specific adenoviruses containing prostate specific promoters may be useful to better target prostate cancer for gene therapy.

AB - Prostate cancer is the most frequent cancer and the second leading cause of cancer deaths in men today. Novel strategies such as gene therapy are desperately needed. Viral-based vectors that are available today for gene therapy are tissue-non-specific because of constitutively active viral promoters. Consequently, the expression of the delivered therapeutic gene may occur in unintended, nontargeted tissues which may potentially cause systemic toxic effects, especially if a suicide gene is the expressed gene. To minimize potential systemic toxicity of adenoviral vectors containing toxic therapeutic genes for gene therapy, prostate-specific promoters may allow the exclusive expression of the therapeutic gene in prostate. Three different prostate-specific promoters, prostate specific antigen (PSA), probasin (PB), and mouse mammary tumor virus long terminal repeat (MMTV), were used to construct adenoviral vectors containing the β-galactosidase (β-gal) reporter gene. The expression and specificity of β-gal gene were evaluated in prostate and nonprostate cells in vitro and in vivo. In vitro, all the three prostate-specific adenoviruses transduced and expressed β-gal in prostate-derived cells, but had weak or no detectable expression of β-gal in non-prostate cells. In vivo, prostate-specific adenoviruses expressed β-gal only in prostate xenograft tumors grown in nude mice, but not in tumors derived from human bladder cancer cells. These results indicate that development of prostate-specific adenoviruses containing prostate specific promoters may be useful to better target prostate cancer for gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032716787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032716787&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032716787

VL - 4

SP - 158

EP - 169

JO - Tumor Targeting

JF - Tumor Targeting

SN - 1351-8488

IS - 3

ER -